EGFR and lung cancer: The complete loss of TP53 function, mainly manifested as single-base substitution and loss of alleles, can catalyze the transformation potential of oncogene drivers in lung cancer and inhibit tumor response to chemotherapy, radiotherapy and EGFR-TKIs (15, 16).